Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma

Table 1 Baseline characteristics of patients with chronic hepatitis B

Variables	n = 240
Age, yr1	48 (27-86)
Gender, M/F	201/39 (84/16)
1Platelet, × 103/mm3	176 (62-556)
Prothrombin time, %1	87 (30-147)
ALT, IU/L1	149 (10-2170)
Total bilirubin, mg/dL1	0.8 (0.3-15.4)
Albumin, g/dL1	4.1 (2.2-5.2)
Serum AFP, ng/mL1	5.9 (1-2150)
Child-Pugh class, A/B/C	216/15/0 (94/6/0)
HBeAg positivity	195 (81)
Serum HBV DNA, copies/mL1	4.2 × 106 (ND-1.1 × 109)
Presence of HBV genotype C	240 (100)
Follow-up periods, mo1	105 (1-237)

¹Median (range). ALT: Alanine aminotransferase; AFP: α-fetoprotein; HBeAg: Hepatitis B e antigen; ND: Not-detected.

Table 2 Univariate analysis of risk factors for hepatocellular carcinoma development

Variables	RR (95%CI)	P value
Genomic changes
C1653T in X region	1.583 (0.176-14.210)	NS
T1753V in X region	17.565 (1.956-157.737)	< 0.01
A1762T/G1764A in BCP	30.512 (0.004-230706)	NS
G1896A in PC	5.765 (0.519-64.076)	NS
Pre-S deletion	2.491 (0.502-12.370)	NS
Clinical characteristics
Age > 50 yr	57.5 (0.035-93428)	NS
Male	27.3 (0.001-547718)	NS
ALT > 80 IU/L	0.55 (0.091-3.29)	NS
PT ≤ 70 %	4.12 (0.682-24.845)	NS
Serum AFP > 200 ng/mL	0.044 (0.00-209046)	NS
HBeAg positive	0.034 (0.00-360.724)	NS
HBV DNA > 105 copies/mL	0.741 (0.123-4.452)	NS

RR: Relative risk; CI: Confidence interval; NS: Not significant; BCP: Basal core promoter; PC: Precore; ALT: Alanine aminotransferase; PT: Prothrombin time; AFP: α-fetoprotein; HBeAg: Hepatitis B e antigen.

Table 3 Multivariate analysis of predisposing factors for hepatocellular carcinoma development

Variables	RR (95%CI)	P value
Age > 50 yr	102903 (0.000-1838)	NS
Male	196796 (0.000-2834)	NS
T1753V in X region	14.029 (1.568-125.550)	< 0.05

NS: Not significant.